13F Holdings
中文EN

TXMD TherapeuticsMD, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 25743 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY33.9%
TTM net income YoY-59.6%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR24.3%
Net income 3-yr CAGR-87.9%

Margins

Gross margin—
Operating margin-95.3%
Net margin3.3%
FCF margin—
EBITDA margin-85.1%

Returns

ROE0.4%
ROA0.3%
ROIC (approx.)-19.0%
Asset turnover0.10x

Leverage & solvency

Liabilities / assets27.2%
Debt / equity0.00x
Current ratio3.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income27.59x
Accruals ratio-8.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.02M$1.76M$1.30M$69.96M$2.57M
Cost of revenue———$1.40M$1.40M
Gross profit——$1.30M$68.57M$1.17M
R&D expense————$7.09M
SG&A expense$6.85M$6.10M$8.90M$56.71M$80.75M
Operating income-$4.39M-$6.11M-$8.52M$1.19M-$79.58M
Interest expense$8,000$10,000$166,600$200,000$32.92M
Pretax income-$653,000-$2.34M-$7.74M$1.07M-$79.31M
Income tax—-$31,000-$43,000——
Net income-$569,000-$2.18M-$10.28M$112.00M-$172.41M
EBITDA-$4.01M-$5.60M-$7.60M$2.38M-$78.84M
EPS (basic)-0.05-0.19-0.9912.41-21.66
EPS (diluted)-0.05-0.19-0.9911.96-21.66
Weighted avg. shares (diluted)11.57M11.53M10,4419.37M7.96M
Balance sheet
Cash & equivalents$7.48M$5.06M$4.33M$49.32M$64.91M
Receivables————$36.18M
Inventory————$7.62M
Current assets$14.45M$12.26M$11.80M$55.35M$119.47M
PP&E, net———$78,000$823,000
Intangibles$3.76M$4.32M$6.10M$6.94M$7.14M
Total assets$37.66M$38.82M$43.31M$90.46M$169.47M
Current liabilities$4.79M$5.17M$6.85M$46.84M$252.89M
Short-term debt————$188.27M
Long-term debt————$0
Total debt————$188.27M
Total liabilities$10.78M$11.45M$14.02M$55.31M$263.09M
Shareholders' equity$26.88M$27.37M$29.29M$35.14M-$93.62M
Net debt————$123.36M
Shares outstanding11.57M11.53M11.53M9.50M8.60M
Cash flow statement
Operating cash flow$2.45M$1.17M-$23.08M$9.36M-$55.13M
Capital expenditure————$34,000
Free cash flow————-$55.17M
Investing cash flow———-$355,000-$2.22M
Financing cash flow——$3.15M-$235.21M$129.55M
Depreciation & amortization$384,000$509,000$922,000$1.19M$736,000
Stock-based compensation$75,000$264,000$1.27M$11.57M$18.12M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.